PGRMC1：绝经激素治疗中乳腺癌风险预测的潜在生物学标志物

doi:10.3969/j.issn.1006-7795.2025.04.001

首都医科大学学报

PGRMC1：绝经激素治疗中乳腺癌风险预测的潜在生物学标志物

王月姣¹,阮祥燕^1，2*,谷牧青¹,魏芸³,管煜伟³,赵越¹,Alfred O.Mueck^1，2

1.首都医科大学附属北京妇产医院/北京妇幼保健院内分泌科，北京 100026；2.德国图宾根大学妇产医院妇女健康部与妇女健康研究中心，图宾根 D-72076；3.北京化工大学化工资源有效利用国家重点实验室，北京 100029

收稿日期:2025-01-23 出版日期:2025-08-21 发布日期:2025-08-29
通讯作者: 阮祥燕 E-mail:ruanxiangyan@ccmu.edu.cn
基金资助:
北京市科技新星计划资助项目(20230484438)，北京市卫生健康委员会北京市研究型病房示范建设项目（BCRW202109），北京市博士后工作经费科研活动资助项目（368456）。

PGRMC1 as a potential biomarker of breast cancer risk for menopausal hormone therapy

Wang Yuejiao¹, Ruan Xiangyan^1，2*, Gu Muqing¹, Wei Yun³, Guan Yuwei³, Zhao Yue¹, Alfred O.Mueck^1，2

1.Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University. Beijing Maternal and Child Health Care Hospital, Beijing 100026, China;2.Department of Women's Health, Research Centre for Women's Health and University Women's Hospital of Tuebingen, University Hospitals of Tuebingen, Tuebingen D-72076, Germany;3.State key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Beijing 100029, China

Received:2025-01-23 Online:2025-08-21 Published:2025-08-29
Supported by:
This study was supported by Beijing Nova Program(20230484438)，Beijing Municipal Health Commission, Demonstration Construction Project of Clinical Research Ward ( BCRW202109)，Beijing Postdoctoral Work Fund for Scientific Research Activities（368456）.

摘要/Abstract

摘要： 孕激素受体膜组分1（progesterone receptor membrane component 1,PGRMC1）属于膜相关孕激素受体(membrane-associated progesterone receptor,MAPR)家族，与激素治疗密切相关。前期大量的体外实验、在体动物实验、乳腺癌患者临床组织样本及血液样本研究结果表明：合成的孕激素（不包括天然孕酮和地屈孕酮）能促进过表达PGRMC1的乳腺癌细胞的快速增殖；在乳腺癌组织中PGRMC1表达越高则乳腺癌肿瘤分级越高、乳腺癌转移发生率越高、预后越差。乳腺癌患者血液中PGRMC1水平与乳腺癌组织中PGRMC1表达呈正相关，相关研究结果表明，血液中PGRMC1在预测早期乳腺癌方面优于传统肿瘤标志物如癌胚抗原（carcino embryonic antigen, CEA）、糖类抗原125（carbohydrate antigen 125, CA125)、CA153等，但仍需要更大样本量的对照研究探索PGRMC1预测乳腺癌风险的灵敏度和特异度，为PGRMC1作为绝经激素替代治疗乳腺癌风险的预测标志物提供理论依据。

关键词: 孕激素受体膜组分1, 孕激素受体膜组分1（PGRMC1）, 绝经激素治疗, 乳腺癌风险, 乳腺癌, 激素安全性

Abstract: Progesterone receptor membrane component 1 (PGRMC1) is closely related to hormone therapy which belongs to the membrane-associated progesterone receptor (MAPR) family. A large number of in vitro experiments, in vivo animal experiments, clinical samples of breast cancer patients and blood studies showed that all synthetic progesterone (excluding natural progesterone and dydrogesterone) can promote the rapid proliferation of breast cancer cells overexpressing PGRMC1. In patients with breast cancer, PGRMC1 is significantly negatively correlated with tumor grade and prognosis, and PGRMC1 level in blood is positively correlated with PGRMC1 expression in breast cancer tissues, and PGRMC1 is superior to traditional tumor markers such as carcinoembryonic antigen (CEA), carbohydrate antigen (CA125), and CA153 in predicting early breast cancer. Therefore, PGRMC1 may serve as a predictive marker for identifying an elevated risk of breast cancer associated with menopausal hormone replacement therapy.

Key words: progesterone receptor membrane component 1, progesterone receptor membrane component 1 (PGRMC1), menopausal hormone therapy;breast cancer risk, breast cancer, hormone safety

中图分类号:

R711

王月姣, 阮祥燕, 谷牧青, 魏芸, 管煜伟, 赵越, Alfred O.Mueck. PGRMC1：绝经激素治疗中乳腺癌风险预测的潜在生物学标志物[J]. 首都医科大学学报, doi: 10.3969/j.issn.1006-7795.2025.04.001.

Wang Yuejiao, Ruan Xiangyan, Gu Muqing, Wei Yun, Guan Yuwei, Zhao Yue, Alfred O.Mueck. PGRMC1 as a potential biomarker of breast cancer risk for menopausal hormone therapy[J]. Journal of Capital Medical University, doi: 10.3969/j.issn.1006-7795.2025.04.001.

参考文献

［1］Parker M, Bucknall M, Jagger C, et al. Population-based estimates of healthy working life expectancy in England at age 50 years: analysis of data from the English longitudinal study of ageing［J］. Lancet Public Health, 2020, 5(7): e395-e403.
［2］陈蓉. 《中国绝经管理与绝经激素治疗指南2023版》解读［J］. 协和医学杂志, 2023, 14(3): 514－519.
［3］Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence［J］. Lancet, 2019, 394(10204): 1159－1168.
［4］阮祥燕, 王月姣. 理性看待绝经激素治疗与乳腺癌发病风险［J］. 协和医学杂志, 2021, 12(2): 163－166.
［5］Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial［J］. JAMA, 2002, 288(3): 321－333.
［6］Chlebowski R T, Anderson G L, Aragaki A K, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the women's health initiative randomized clinical trials［J］. JAMA, 2020, 324(4): 369－380.
［7］Manson J E, Crandall C J, Rossouw J E, et al. The women's health initiative randomized trials and clinical practice:a review［J］. JAMA, 2024, 331(20): 1748－1760.
［8］Ruan X Y, Mueck A O. Clinical importance of PGRMC1 in hormone responsive breast cancer［J］. Breast Care, 2023, 18(3): 172－178.
［9］Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort［J］. Int J Cancer, 2005, 114(3): 448－454.
［10］Mohammed H, Russell I A, Stark R, et al. Progesterone receptor modulates ERα action in breast cancer［J］. Nature, 2015, 523(7560): 313－317.
［11］Ruan X Y, Zhang Y, Mueck A O, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer［J］. Menopause, 2017, 24(2): 203－209.
［12］Zhang L, Ruan X, Gu M, et al. E2+norethisterone promotes the PI3K-AKT pathway via PGRMC1 to induce breast cancer cell proliferation［J］. Climacteric, 2022, 25(5): 467－475.
［13］Bai Y X, Ludescher M, Poschmann G, et al. PGRMC1 promotes progestin-dependent proliferation of breast cancer cells by binding prohibitins resulting in activation of ERα signaling［J］. Cancers, 2021, 13(22): 5635.
［14］Xu X, Ruan X Y, Zhang Y, et al. Comprehensive analysis of the implication of PGRMC1 in triple-negative breast cancer［J］. Front Bioeng Biotechnol, 2021, 9: 714030.
［15］Craven R J. PGRMC1: a new biomarker for the estrogen receptor in breast cancer［J］. Breast Cancer Res, 2008, 10(6): 113.
［16］Neubauer H, Ma Q, Zhou J, et al. Possible role of PGRMC1 in breast cancer development［J］. Climacteric, 2013, 16(5): 509－513.
［17］Cai G J, Wang Y J, Houda T, et al. MicroRNA-181a suppresses norethisterone-promoted tumorigenesis of breast epithelial MCF10A cells through the PGRMC1/EGFR－PI3K/Akt/mTOR signaling pathway［J］. Transl Oncol, 2021, 14(6): 101068.
［18］Zhao Y, Ruan X, Cheng J, et al. PGRMC1 promotes triple-negative breast cancer cell growth via suppressing ferroptosis［J］. Climacteric, 2023, 26(2): 135－142.
［19］Wang Y, Tahiri H, Yang C, et al. Overexpression of miR-181a regulates the Warburg effect in triple-negative breast cancer［J］. Climacteric, 2023, 26(1): 64－71.
［20］Gu M Q, Wang L J, Yang C, et al. Micro-RNA-181a suppresses progestin-promoted breast cancer cell growth［J］. Maturitas, 2018, 114: 60－66.
［21］Pedroza D A, Ramirez M, Rajamanickam V, et al. miRNome and functional network analysis of PGRMC1 regulated miRNA target genes identify pathways and biological functions associated with triple negative breast cancer［J］. Front Oncol, 2021, 11: 710337.
［22］Zhang Y, Ruan X Y, Mi X, et al. Expression of PGRMC1 in paraffin-embedded tissues of breast cancer［J］. Int J Clin Exp Pathol, 2017, 10(9): 9639－9643.
［23］Zhang Y, Ruan X Y, Willibald M, et al. May progesterone receptor membrane component 1 (PGRMC1) predict the risk of breast cancer?［J］. Gynecol Endocrinol, 2016, 32(1): 58－60.
［24］Li X, Ruan X, Gu M, et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol［J］. Climacteric, 2019, 22(5): 483－488.
［25］Ruan X Y, Mueck A O. Systemic progesterone therapy-oral, vaginal, injections and even transdermal?［J］. Maturitas, 2014, 79(3): 248－255.
［26］赵越, 阮祥燕, 谷牧青, 等. PGRMC1在激素治疗中促进乳腺癌细胞增殖的机制研究［J］. 中国癌症防治杂志, 2022, 14(4): 378－384.
［27］赵越, 阮祥燕. PGRMC1在激素补充治疗中对乳腺癌增殖风险及机制的研究进展［J］. 医学综述, 2022, 28(6): 1097－1102.
［28］Ruan X Y, Gu M Q, Cai G J, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study［J］. Maturitas, 2019, 123: 1－8.
［29］Cai G J, Ruan X Y, Gu M Q, et al. PGRMC1 in animal breast cancer tissue and blood is associated with increased tumor growth with norethisterone in contrast to progesterone and dydrogesterone: four-arm randomized placebo-controlled xenograft study［J］. Gynecol Endocrinol, 2020, 36(11): 1024－1027.
［30］蔡桂举, 阮祥燕. 孕激素受体膜组分1在绝经后激素治疗中乳腺癌风险预测的研究进展［J］. 实用医学杂志, 2021, 37(13): 1769－1773.

[1]	田玄玄, 阮祥燕, 赵越, 金婧, 柳顺玉, 蒋玲玲. 个体化生活方式干预对多囊卵巢综合征肥胖患者性功能的影响[J]. 首都医科大学学报, 2025, 46(4): 614-619.
[2]	赵越, 阮祥燕, 邹丽颖, 马郡, 王月姣, 田玄玄, 金婧. 孕早期甲状腺功能正常妇女甲状腺自身免疫与妊娠期糖尿病的相关性研究[J]. 首都医科大学学报, 2025, 46(4): 626-631.
[3]	马郡, 阮祥燕, 许仲婷, 赵越, 王月姣, Alfred O.Mueck. 来曲唑联合资癸女贞胶囊对多囊卵巢综合征子宫内膜薄性不孕患者的疗效观察[J]. 首都医科大学学报, 2025, 46(4): 632-636.
[4]	王婧, 周巧云, 王牧雨, 肖豫, 宋冬梅, 郭艳, 夏恩兰, 李天照, 黄晓武. 绝经后出血子宫内膜癌危险因素分析及预测模型的建立[J]. 首都医科大学学报, 2025, 46(1): 143-149.
[5]	裴友娟, 阮祥燕, 鞠蕊, 王月姣, 蒋玲玲, 马郡. 人工智能在生殖内分泌领域中的应用[J]. 首都医科大学学报, 2024, 45(4): 566-572.
[6]	李扬璐, 阮祥燕, 李妍秋, 谷牧青, 杜娟, 王泽铖, 程姣姣, 金凤羽, 蒋玲玲, 杨瑜, Alfred O. Mueck. N-乙酰半胱氨酸对冻融人卵巢组织的保护作用[J]. 首都医科大学学报, 2024, 45(4): 573-582.
[7]	王泽铖, 阮祥燕, 杨瑜, 李婧, Alfred O. Mueck. 医源性早发性卵巢功能不全性激素水平的变化及对糖代谢的影响[J]. 首都医科大学学报, 2024, 45(4): 583-588.
[8]	王志坤, 阮祥燕, 刘莉莉, 杨瑜, 蒋玲玲, 王泽铖, Alfred O.Mueck. 绝经过渡期和绝经后期女性睾酮水平对女性性功能的影响[J]. 首都医科大学学报, 2024, 45(4): 589-595.
[9]	刘莉莉, 阮祥燕, 杨瑜, 蒋玲玲, 王泽铖, 张明珍, Alfred O.Mueck. 围绝经期及绝经后期女性人体体成分与腰椎骨密度的相关分析[J]. 首都医科大学学报, 2024, 45(4): 596-601.
[10]	赵越, 阮祥燕, 王月姣, 马郡, 金婧. 女性雄性激素质谱多指标检测在多囊卵巢综合征诊断中的应用[J]. 首都医科大学学报, 2024, 45(4): 602-608.
[11]	田玄玄, 阮祥燕, 金婧, 鞠蕊, 杜娟, 程姣姣, 杨瑜. 多囊卵巢综合征患者不同临床表型的性功能分析[J]. 首都医科大学学报, 2024, 45(4): 616-622.
[12]	蒋玲玲, 阮祥燕, 李妍秋, 张明珍, 王泽铖, 杨瑜, 刘莉莉, Alfred O. Mueck. 多囊卵巢综合征患者体成分对肝、肾功能和血脂的影响[J]. 首都医科大学学报, 2024, 45(4): 623-628.
[13]	杜娟, 阮祥燕. 卵巢组织冻存与移植技术新进展[J]. 首都医科大学学报, 2024, 45(4): 629-635.
[14]	中国人体健康科技促进会生育力保护与保存专业委员会, 国际妇科内分泌学会中国妇科内分泌学分会, 北京妇产学会内分泌分会, 中华预防医学会生育力保护分会, 中国妇幼健康研究会生殖内分泌专业委员会. 卵巢组织冻存移植防治医源性早发性卵巢功能不全临床应用指南[J]. 首都医科大学学报, 2023, 44(5): 695-703.
[15]	巫剑红, 田玉翠, 蒋子雯, 唐世倩, 刘朝晖, 代荫梅. LncRNA FAM95B1调控胰岛素样生长因子2的表达对宫腔粘连发生的影响[J]. 首都医科大学学报, 2023, 44(5): 821-827.

PGRMC1：绝经激素治疗中乳腺癌风险预测的潜在生物学标志物

PGRMC1 as a potential biomarker of breast cancer risk for menopausal hormone therapy

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价